← All indications
Muscular Disorders, Atrophic
Disorders characterized by an abnormal reduction in muscle volume due to a decrease in the size or number of muscle fibers. Atrophy may result from diseases intrinsic to muscle tissue (e.g., MUSCULAR DYSTROPHY) or secondary to PERIPHERAL NERVOUS SYSTEM DISEASES that impair innervation to muscle tissue (e.g., MUSCULAR ATROPHY, SPINAL).
Subtype terms (2)
More specific conditions that are subtypes of Muscular Disorders, Atrophic in the MeSH hierarchy.
- Muscular Dystrophies
44 drugs (19 approved, 25 experimental)
- Postpoliomyelitis Syndrome
8 drugs (6 approved, 2 experimental)
Drugs by status
Phase 3 trials (2)
Phase 2 trials (1)
Phase 1 trials (1)
Other trials (3)
Organizations
Organization Involved with Phase 3 Indications (1)
Organization Involved with Phase 2 Indications (2)
Organization Involved with Other Experimental Indications (4)